| |
Subscription-based business models are vital for successful direct-to-consumer (DTC) testing. Discover the ins and outs of DTC testing and how to outlast the competition in this free guide. Download Now.
|
|
Today's Big NewsJan 10, 2023 |
|
March 14-15, 2023 | San Francisco, CA Gain valuable insight from cross-functional team members responsible for search and evaluation, legal/IP, portfolio management, strategic alliances, business development and licensing. Register today to secure our lowest rates!
|
|
| By Gabrielle Masson Eli Lilly’s plate is full this year, CMO says from the sidelines of the J.P. Morgan Healthcare conference, with five potential launches cooking and 10 top priorities. |
|
|
|
By Max Bayer Roivant CEO Matt Gline has his foot on the clinical pedal heading, saying 2023 could be the "single most exciting" year for the company with respect to new readouts. The news comes just one week after the company posted competitive phase 2 data of its ulcerative colitis med. |
By Nick Paul Taylor Jasper Therapeutics spent the past 11 months working to kick off a phase 3 blood cancer trial. Now, with the first-quarter start date in sight, the biotech has pulled a volte-face, dropping plans to start the pivotal study and switching its focus to other indications. |
Sponsored by Personalis Advanced ctDNA analysis yields biomarkers of cancer dynamics essential in therapeutic monitoring & intervention. Learn how NeXT Personal® detects MRD, monitors variants, & delivers powerful insights. |
|
Thursday, January 19, 2023 | 11:00am ET In this webinar, hear how Novartis uses social data from public forums worldwide to understand the educational and emotional needs of patients with Myelodysplastic Syndromes (MDS), and thereby create more targeted solutions to meet these needs. Register now.
|
|
By Annalee Armstrong Beam Therapeutics CEO John Evans is well aware that sickle cell is a crowded area when it comes to gene editing therapies, but as data roll in, each candidate is beginning to differentiate itself. |
By Annalee Armstrong Mirati Therapeutics became a commercial organization last year with the approval of adagrasib, now known as Krazati, and the company is churning out its next candidates. While that means a loaded pipeline, CEO David Meek, in a nod to the tough market conditions facing biotechs at the moment, said the company won't be afraid to cut and run if any of the assets don't prove their worth. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong,James Waldron All you need to know from the second day of the J.P. Morgan Healthcare Conference. |
By James Waldron Alto Neuroscience has pointed to the success of its antidepressant therapy in a phase 2a trial as proof that its precision psychiatry platform can identify the patients most likely to benefit from its treatment. |
By Nick Paul Taylor AbbVie has joined Anima Biotech’s star-studded roster of partners, paying $42 million upfront to work with the biotech on small-molecule mRNA drugs against three “undruggable” targets in oncology and immunology. |
By James Waldron,Annalee Armstrong,Nick Paul Taylor,Max Bayer Join us for a rolling look at the top life sciences news coming out of this year's J.P. Morgan Healthcare Conference. |
By James Waldron Calithera Biosciences has kept its head down since a phase 2 fail in 2021 caused it to lay off a third of its workforce. But in the wake of enrollment delays to its two lead cancer therapies, the cash-strapped biotech has given up the fight and announced it’s liquidating the business. |
By James Waldron Seven months after Day One posted positive initial data for its brain tumor drug, the therapy still appears to be on track for success—proving its effectiveness in a phase 2 trial. |
By Helen Floersh Systematically profiling the way pancreatic cancer cells suppress the immune system led scientists to a treatment that showed long-term, disease-free survival of up to 90% in mouse models. |
By Andrea Park In interviews with Fierce Medtech during the annual J.P. Morgan Healthcare Conference on Monday, leaders from Freenome, Babson Diagnostics and Immunexpress discussed their ongoing plans to make a wide range of blood tests as broadly accessible and as simple to use as possible. |
By Eric Sagonowsky,Zoey Becker,Angus Liu,Fraiser Kansteiner,Kevin Dunleavy On the second day of the J.P. Morgan Healthcare Conference, GSK, Bayer, Roche and many others are set to share updates about their operations. |
By Andrea Park In an interview with Fierce Medtech at the J.P. Morgan Healthcare Conference, Invitae CEO Kenneth Knight discussed how the nearly two decades he spent at General Motors, Caterpillar and Amazon prepared him to lead a genetic testing company. |
By Nick Paul Taylor Rani Therapeutics has secured a supply of ustekinumab for an oral drug delivery program, partnering with Celltrion to access materials for its development of a biosimilar rival to Johnson & Johnson’s Stelara. The deal gives Celltrion the right of first negotiation on the oral ustekinumab biosimilar program. |
By Paige Minemyer SAN FRANCISCO—Last year, Humana was forced to slash its estimates for Medicare Advantage enrollment growth, and the news dominated the payer industry conversation at the J.P. Morgan Healthcare Conference. |
Fierce podcastsDon't miss an episode |
| This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week. |
|
|---|
|
|
|
Tuesday, January 24, 2023 | 1:00pm ET This session will discuss key 2023 trends for healthcare and life sciences and how organizations should think about their data strategy and interoperability as they navigate the winds of change. Register now.
|
|
| WhitepaperThis paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Executive Summary Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| WhitepaperLearn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| |
|
